Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
This observational study aims to describe demographic, clinical characteristics, treatment patterns outcomes of participants with advanced Renal Cell Carcinoma (aRCC) receiving either Nivolumab + Ipilimumab, or Pembrolizumab + Lenvatinib combination therapy
Advanced Renal Cell Carcinoma (aRCC)
COMBINATION_PRODUCT: Nivolumab + Ipilimumab combination therapy|COMBINATION_PRODUCT: Pembrolizumab + Lenvatinib combination therapy
Participant year of birth, Baseline|Participant sex at birth, Baseline|Participant primary payer, Baseline|Participant race, Baseline|Participant ethnicity, Baseline|Participant U.S. state of residence, Baseline|Participant initial Renal Cell Carcinoma (RCC) diagnoses, Baseline|American Joint Committee on Cancer (AJCC) TNM stage, Baseline|Participant advanced/metastatic Renal Cell Carcinoma (RCC) diagnosis, Baseline|Participant renal cell carcinoma (RCC) histology results, Baseline|Participant tumor grade, Baseline|Participant biomarker or genetic testing method, Baseline|Participant molecular and/or genetic mutations reported, Baseline|Participant site of metastatic disease, Index date|Participant Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), Baseline|Participant Karnofsky score (KPS), Baseline|Participant comorbidities and/or chronic conditions, Baseline|Participant blood test results, Index date|Participant Memorial Sloan Kettering Cancer Center (MSKCC) score, Index date|Participant International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) score, index date|Participant smoking status, Baseline|Participant COVID-19 status, Baseline|Participant surgical history, Baseline|Participant radiation treatment history, Baseline|Participant treatment regimen received, Index date up to 32 months|Participant treatment initiation and discontinuation dates, Index date up to 32 months|Participant rationale for discontinuation of treatment, Index date up to 32 months|Participant radiation therapy prescribed, Index date up to 32 months|Participant total number of radiotherapy cycles, Index date up to 32 months|Participant initial dose and frequency/schedule of index therapy, Index date up to 32 months|Participant index treatment dose modifications, Index date up to 32 months|Participant rationale for dose modifications of index therapy, Index date up to 32 months|Participant date of dose modifications of index therapy, Index date up to 32 months|Participant last dose and frequency/schedule of index therapy, Index date up to 32 months
This observational study aims to describe demographic, clinical characteristics, treatment patterns outcomes of participants with advanced Renal Cell Carcinoma (aRCC) receiving either Nivolumab + Ipilimumab, or Pembrolizumab + Lenvatinib combination therapy